During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to the Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR. We asked, When can we safely discontinue interferon alpha therapy in patients with myeloproliferative neoplasms?

Results from several studies have shown that interferon alpha is able to induce high rates of complete hematological remission in patients with polycythemia vera, but what are the outcomes in patients who had received interferon alpha and then discontinued treatment?

Kiladjian reports the results of a study comparing the clinical outcome of patients with myeloproliferative neoplasms who discontinued therapy after at least three months of interferon alpha treatment to patients who continued interferon alpha treatment despite achieving a complete hematological remission.

Hosted on Acast. See acast.com/privacy for more information.